A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT02280083
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 180 participants
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
- Registry
-
NCT02280083
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02280083. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
- Condition
- Cerebrovascular Accident
- Intervention (Drug)
- Botulinum Toxin Type A for Injection
- Intervention (Drug)
- placebo
- Lead sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Record details
- Record id
cardio:ct-nct02280083- Content hash
1b142bf7efe5ae006c5f5e78b1c51ac1ae485ddd30e0fa53a5ed147185be2afb